About Bio Medica Laboratories IPO
Bio Medica Laboratories IPO Details
Bio Medica Laboratories IPO is a 100% book-built issue of 37.71 lakh equity shares worth up to ₹52 Cr, comprising a fresh issue of 33.94 lakh equity shares worth up to ₹47 crore and an offer for sale (OFS) of 3.76 lakh equity shares worth up to ₹5 crore, with a face value of ₹10 per share. The company filed its DRHP with SEBI on August 08, 2025.
The price band of this issue is set between ₹132 and ₹139 per share and the lot size for an application is 1,000 shares. The minimum amount of investment required by an individual investor (retail investor) is ₹2,78,000 (2,000 shares). The IPO will be open from May 21 to 25, 2026, on the NSE SME platform, with a tentative listing date fixed as May 29, 2026. The book-running lead manager of this issue is Narnolia Financial Services Ltd., while the registrar to the issue is Skyline Financial Services Pvt. Ltd.
Bio Medica Laboratories IPO Date & Timeline
The Bio Medica Laboratories IPO is officially set to open for subscription on May 21, 2026 and will close on May 25, 2026. The company initially filed its Draft Red Herring Prospectus (DRHP) on August 08, 2025 and has now finalized its schedule following SEBI approval. Once the subscription window allotment is expected on May 26, 2026. Following this, the company will initiate refunds and credit shares to successful investors' demat accounts on May 27, 2026. Finally, Bio Medica Laboratories Ltd.'s shares are tentatively scheduled to list on the stock exchanges on May 29, 2026.
Bio Medica Laboratories IPO Timeline
| IPO Open Date | Thu, May 21, 2026 |
| IPO Close Date | Mon, May 25, 2026 |
| Tentative Allotment | Tue, May 26, 2026 |
| Initiation of Refunds | Wed, May 27, 2026 |
| Credit of Shares to Demat | Wed, May 27, 2026 |
| Tentative Listing Date | Fri, May 29, 2026 |
| Cut-off time for UPI mandate confirmation | - |
Bio Medica Laboratories IPO Details
| Detail | Description |
|---|---|
| IPO Date | 21 to 25 May, 2026 |
| Listing Date | 29 May, 2026 |
| Face Value | ₹ 10 per share |
| Issue Price Band | ₹ 132 to ₹ 139 |
| Lot Size | 1,000 Shares |
| Sale Type | Fresh capital cum OFS |
| Total Issue Size | 37,72,000 shares (agg. up to ₹ 52 Cr) |
| Reserved for Market Maker | 1,89,000 shares (agg. up to ₹ 3 Cr) Prabhat Financial Services Ltd. |
| Fresh Issue(Ex Market Maker) | 32,06,000 shares (agg. up to ₹ 45 Cr) |
| Offer for Sale | 3,77,000 shares of ₹10 (agg. up to ₹ 5 Cr) |
| Net Offered to Public | 35,83,000 shares (agg. up to ₹ 50 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 91,80,001 shares |
| Share Holding Post Issue | 1,25,75,001 shares |
Bio Medica Laboratories IPO GMP (Grey Market Premium)
“Grey Market Premium” or GMP is defined as the rate at which the IPO's shares are traded in the market before they are officially listed on the stock exchange.
The Bio Medica Laboratories IPO GMP is currently trading at ₹-6, reflecting the sentiment of unofficial investors before the official listing. This premium suggests a potential listing price of ₹133, which is (-4.32%) above the issue price. While the Grey Market Premium is a key indicator of demand and investor appetite, it is important to remember that GMP is highly volatile and should not be the sole factor in your investment decisions.
IPO Estimated Listing Return
Based on the IPO Price of ₹139 (highest price band), the latest uploaded Grey Market Premium (GMP) of ₹-9 and a lot size of 1000 shares.
Bio Medica Laboratories GMP TREND (DAILY UPDATES)
| GMP Date | IPO Price | GMP | Last Updated |
|---|---|---|---|
| 29 May 2026 | ₹139 | ₹-9 | 29 May, 202611:49 AM |
| 28 May 2026 | ₹139 | ₹-6 | 28 May, 202609:42 AM |
| 27 May 2026 | ₹139 | ₹-6 | 27 May, 202605:58 PM |
| 26 May 2026 | ₹139 | ₹-6 | 26 May, 202610:42 AM |
| 25 May 2026 | ₹139 | ₹0 | 25 May, 202610:10 AM |
| 24 May 2026 | ₹139 | ₹0 | 25 May, 202610:10 AM |
| 23 May 2026 | ₹139 | ₹0 | 23 May, 202609:52 AM |
| 22 May, 2026 | ₹139 | ₹0 | 23 May, 202609:52 AM |
| 21 May, 2026 | ₹139 | ₹35 | 23 May, 202609:52 AM |
| 20 May, 2026 | ₹139 | ₹0 | 23 May, 202609:52 AM |
| 19 May, 2026 | ₹139 | ₹0 | 23 May, 202609:52 AM |
| 18 May, 2026 | ₹139 | ₹0 | 23 May, 202609:52 AM |
Company Background
Bio Medica Laboratories Ltd. was incorporated on August 14, 2015, as a private limited company in Indore, Madhya Pradesh and then on October 24, 2024, the company transformed into a public limited company to proceed with its public listing procedures.
The company's main focus is on the pharmaceutical manufacturing sector, as they manufacture a variety of products, comprising ethical drugs, generic drugs and OTC drugs; injectables in the form of liquid and dry powder, which address multiple medical issues and preferences.
Operations & Product Range
Bio Medica Laboratories Ltd is basically involved in the manufacture of parenteral formulations in the pharmaceutical industry. The primary strength of the organization comes from the ability to produce injectable formulations of two types, including the liquid injection formulation as well as the dry powder injection. The products come in the form of single-dose and multi-dose formulations.
Facilities & Capacity
The manufacturing activities of Bio Medica Laboratories Ltd. are centralized at the company’s manufacturing facility, which is situated in the state of Madhya Pradesh. The facility has been set up in accordance with the requirements for sterile injectable manufacturing, which entails operating under specific environmental conditions and using specialized equipment to fill liquids and powders. With this listing, the company aims to fund its operational infrastructure to increase its installed capacity to meet increasing order volumes and enhance its manufacturing efficiency.
Brands & Market Presence
Bio Medica Laboratories Ltd. has created a niche for itself within the Indian pharmaceutical industry, owing to its unique injectables range as well as its contract manufacturing operations that involve formulations for other pharmaceutical companies. It works on a model of parenteral formulations that are branded and supplied to healthcare practitioners as well as veterinarians. It has a stronghold in the domestic market with a wide customer base that includes hospitals and pharmaceutical wholesalers.
Revenue Streams & Business Model
The primary revenue source for Bio Medica Laboratories Ltd. is the sale of its pharmaceutical parenteral formulations. The business model is structured around two key pillars, which include the manufacturing of its own branded generics and ethical drugs and the other is providing contract manufacturing services to additional pharmaceutical companies.
For FY25, the company has reported its revenue from operations at ₹38.19 crore and PAT was at ₹9.79 crore. While the majority of revenue is currently derived from domestic operations, the firm's business model is designed to scale and potentially explore export opportunities as it expands its manufacturing capacity.
Management & Shareholding
Bio Medica Laboratories Ltd. is led by its promoters, Mr. Mukesh Mehta and Mr. Pradeep Mehta. Before the IPO, the promoters held a 99.99% stake in the company, but after the IPO, the promoters' shareholding will be diluted as the offering includes an OFS of up to ₹5 crore.
Board & Key Management
The leadership of Bio Medica Laboratories Ltd. is led by a team of experts with many years of experience. Mr. Pradeep Mehta serves as the Chairman and gives strategic direction to the firm. The daily operations are managed by Mr. Pradeep Mehta, the Managing Director, along with Whole-Time Director Mr. Mukesh Mehta. To ensure good governance, the board includes Independent Directors Ms. Divya Khandelwal and Mr. Sumeet Bansal for honest oversight. Together, this team uses its knowledge to help the company grow and stay successful.
Bio Medica Laboratories IPO Financial Information
Latest Revenue
28.54
₹ Crore
Profit After Tax
8.66
₹ Crore
Net Worth
17.12
₹ Crore
Total Borrowing
38.17
₹ Crore
| Period Ended | Assets | Revenue From Operations | Profit After Tax | Net Worth | Reserves & Surplus | Total Borrowing | |||
|---|---|---|---|---|---|---|---|---|---|
| 30 Nov 2025 | 65.17 | 28.54 | 8.66 | 17.12 | 7.94 | 38.17 | |||
| 31 Mar 2025 | 39.12 | 38.19 | 9.79 | 14.73 | 5.55 | 15.01 | |||
| 31 Mar 2024 | 19.5 | 15.24 | 2.50 | 4.94 | 4.84 | 10.49 | |||
| 31 Mar 2023 | 17.57 | 16.22 | 0.33 | 2.44 | 2.34 | 9.61 | |||
| Amount in ₹ Crore | |||||||||
Bio Medica Laboratories Key Performance Indicator
| KPI | Values |
|---|---|
| ROE | 54.41% |
| ROCE | 23.22% |
| Debt/Equity | 2.23 |
| RoNW | 54.41% |
| PAT Margin | 30.35% |
| EBITDA Margin | 47.11% |
| Price to Book Value | - |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 10.67 | 10.33 |
| P/E (x) | 13.03 | 13.45 |
Bio Medica Laboratories IPO Objectives
The company intended to utilize Bio Medica Laboratories Ltd. for strategic purposes:
- • Repayment of debt
- • Funding the setup of its new manufacturing facilities
- • General corporate purposes
Bio Medica Laboratories IPO Review
Bio Medica Laboratories Ltd. is one of the rapidly growing companies in the injectable drugs industry, providing its services to both humans and animals. Its strategy includes the use of a business model based on selling through brands as well as manufacturing products for other companies. Due to its specialization in producing parenteral formulations, which requires stricter regulations, the company is positioned among medium-sized pharmaceutical companies.
Financially, the company has shown growing and healthy financial statements, as the revenue from operations was reported at ₹38.19 crore, with an EBITDA of 15.21 crore and a margin of 39.83%, while for FY24, the EBITDA margin was 36.93%.
However, investors should consider the inherent risks associated with the pharmaceutical industry, such as operating in a highly growing market where any failure to maintain quality standards or renew licenses could impact operations. Moreover, as an Indore-based firm with a centralised manufacturing unit, it faces geographic concentration risks. The successful utilisation of IPO proceeds for expansion will be a key factor in maintaining its growth momentum.
Conclusion
The Bio Medica Laboratories IPO is an opportunity for an investor to invest in a growing company that has successfully carved out a place in the specialized injectable drug market, with a strong focus on both human and veterinary products and a recent surge in financial performance. This IPO offers an interesting look at a mid-sized pharmaceutical player aiming to leverage its manufacturing expertise for long-term success.
Frequently Asked Questions
Recommended Advisory Services
Ready to take your company public? Explore our specialized IPO advisory services tailored for Indian enterprises.
The India IPO Publication is managed by an editorial team that includes highly experienced finance journalists, market researchers and professionals from the capital markets industry who strive to create high-quality content based on credible sources. Our editors write about IPOs, capital markets, corporate news, capital-raising strategies, regulations and other business matters to ensure our audience stays updated with the latest information. We conduct detailed research and fact-check all information before publishing any content to ensure credibility.
Competitive Strengths
A wide range of product lines, emphasizing especially the formulation of products in their parenteral forms, such as liquid or dry powder injection for humans as well as animals.
Financial growth, which includes an increase of over 150% in terms of sales and a considerable rise in PAT within the current financial year.
Business model comprising a combination of both branded products marketing and manufacturing operations, contributing equally to the company’s revenue.
The strategic manufacturing unit located at Indore, Madhya Pradesh, is based in an industrial zone where all the necessary inputs are available.
Download regulatory filings
IPO Lot Size
| Investors | No.of lots | Shares Offered | Max Bid Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 2 | 2000 | 278000 |
| Individual investors (Retail) (Max) | 2 | 2000 | 278000 |
| S-HNI (Min) | 3 | 3000 | 417000 |
| S-HNI (Max) | 7 | 7000 | 973000 |
| B-HNI (Min) | 8 | 8000 | 1112000 |